File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Bazedoxifene: A new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis

TitleBazedoxifene: A new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis
Authors
Issue Date2009
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop
Citation
Expert Opinion On Pharmacotherapy, 2009, v. 10 n. 8, p. 1377-1385 How to Cite?
AbstractBazedoxifene acetate (WAY-140424; TSE-424) is an oral, nonsteroidal, indole-based selective estrogen receptor modulator (SERM) being developed for the prevention and treatment of osteoporosis. Preclinical studies on bazedoxifene have demonstrated estrogen agonist effects on the skeleton and lipid metabolism but not on breast and uterine endometrium. In combination with estrogen, bazedoxifene antagonizes the stimulatory action of estrogens on proliferation of breast cancer cells and endometrium. Phase III clinical studies have shown favorable effects on the skeleton without stimulation of endometrium and breast. Bazedoxifene prevents bone loss in postmenopausal women without osteoporosis and reduces vertebral fractures in women with postmenopausal osteoporosis. In women at high risk of fracture with multiple risk factors, bazedoxifene reduces nonvertebral fracture risk in post-hoc analysis. Bazedoxifene in combination with conjugated estrogens represents a new form of therapeutic agents for the treatment of postmenopausal symptoms and prevention of postmenopausal osteoporosis. Clinical trials with bazedoxifene/conjugated estrogens have shown beneficial effects on bone mineral density and bone turnover markers with improvement in vasomotor symptoms and little or no stimulation of breast and endometrium. © 2009 Informa UK Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/59182
ISSN
2015 Impact Factor: 3.543
2015 SCImago Journal Rankings: 0.884
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorChu, EYWen_HK
dc.contributor.authorXu, Len_HK
dc.date.accessioned2010-05-31T03:44:29Z-
dc.date.available2010-05-31T03:44:29Z-
dc.date.issued2009en_HK
dc.identifier.citationExpert Opinion On Pharmacotherapy, 2009, v. 10 n. 8, p. 1377-1385en_HK
dc.identifier.issn1465-6566en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59182-
dc.description.abstractBazedoxifene acetate (WAY-140424; TSE-424) is an oral, nonsteroidal, indole-based selective estrogen receptor modulator (SERM) being developed for the prevention and treatment of osteoporosis. Preclinical studies on bazedoxifene have demonstrated estrogen agonist effects on the skeleton and lipid metabolism but not on breast and uterine endometrium. In combination with estrogen, bazedoxifene antagonizes the stimulatory action of estrogens on proliferation of breast cancer cells and endometrium. Phase III clinical studies have shown favorable effects on the skeleton without stimulation of endometrium and breast. Bazedoxifene prevents bone loss in postmenopausal women without osteoporosis and reduces vertebral fractures in women with postmenopausal osteoporosis. In women at high risk of fracture with multiple risk factors, bazedoxifene reduces nonvertebral fracture risk in post-hoc analysis. Bazedoxifene in combination with conjugated estrogens represents a new form of therapeutic agents for the treatment of postmenopausal symptoms and prevention of postmenopausal osteoporosis. Clinical trials with bazedoxifene/conjugated estrogens have shown beneficial effects on bone mineral density and bone turnover markers with improvement in vasomotor symptoms and little or no stimulation of breast and endometrium. © 2009 Informa UK Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eopen_HK
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_HK
dc.subject.meshClinical Trials as Topicen_HK
dc.subject.meshHumansen_HK
dc.subject.meshIndoles - therapeutic useen_HK
dc.subject.meshOsteoporosis, Postmenopausal - drug therapyen_HK
dc.subject.meshSelective Estrogen Receptor Modulators - therapeutic useen_HK
dc.titleBazedoxifene: A new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosisen_HK
dc.typeArticleen_HK
dc.identifier.emailKung, AWC:awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14656560902980228en_HK
dc.identifier.pmid19445558-
dc.identifier.scopuseid_2-s2.0-67649690531en_HK
dc.identifier.hkuros158951en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-67649690531&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1377en_HK
dc.identifier.epage1385en_HK
dc.identifier.isiWOS:000267235800014-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridKung, AWC=7102322339en_HK
dc.identifier.scopusauthoridChu, EYW=26666500500en_HK
dc.identifier.scopusauthoridXu, L=7404744597en_HK
dc.identifier.citeulike4690753-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats